Table 3 Five-year relative survival and RER stratified by stage

From: Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group

 

RS

95% CI

Crude RER

95% CI

P

Adjusted RER

95% CI

P

Stage I

  Belgium

97.3

96.2–98.1

Reference

  

Reference

  

  Greater Poland

103.2

103.2–103.3

NA#

 

0.543

0.18#

0.001–3000#

0.996

  Ireland

99.4

89.0–100.0

NA#

 

0.702

0.43#

0.001–377#

0.805

  The Netherlands

96.0

95.5–96.5

0.81

0.24–2.72

0.402

1.32

0.46–3.84

0.547

  England

93.4

93.1–93.7

1.13

1.04–6.10

0.004

2.96

1.30–6.72

 < 0.001

Stage II

  Belgium

85.2

84.3–86.1

Reference

  

Reference

  

  Ireland

86.3

84.9–87.7

0.92

0.69–1.23

0.574

0.94

0.72–1.22

0.625

  The Netherlands

82.5

82.0–83.1

1.10

0.94–1.30

0.224

1.02

0.87–1.18

0.828

  Greater Poland

85.3

80.7–88.9

1.26

0.72–2.20

0.418

1.46

0.79–2.69

0.227

  England

79.1

78.8–79.4

1.43

1.24–1.66

 < 0.001

1.45

1.27–1.66

 < 0.001

Stage III

  Belgium

60.1

58.7–61.7

Reference

  

Reference

  

  Greater Poland

58.5

52.7–63.8

1.33

0.91–1.95

0.139

1.51

1.05–2.18

0.026

  The Netherlands

55.1

54.1–56.0

1.24

1.00–1.52

0.046

1.07

0.90–1.27

0.418

  Ireland

53.5

51.3–55.7

1.40

1.18–1.67

 < 0.001

1.27

1.07–1.50

0.007

  England

48.2

47.8–48.7

1.56

1.40–1.74

 < 0.001

1.46

1.31–1.62

 < 0.001

  1. Countries were ranked according to the sum of proportions of each given treatment and the country with the highest sum of given treatment was assigned as reference country. n/N: numbers of events/numbers at risk, RS: 5-year relative survival, 95% CI: 95% confidence interval, crude RER: univariate relative excess risk, adjusted RER: multivariable relative excess risk, adjusted for the following confounders: age (continuous), year of diagnosis, grade, morphology. NA: not addressed. # Owing to low excess mortality, RER could not be interpreted